Glenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agre...

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVi...

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio a...

Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...

The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...

Glenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...

Markets declined on weekly expiry day, with several companies in focus due to earnings and news. TCS reported a 6% profit increase, while I...

Glenmark Pharma Share Price: Glenmark Pharmaceuticals' shares soared after its subsidiary, Ichnos Glenmark Innovation, inked a global licen...

Glenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating...

Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated ...

Glenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...

Nomura, BNP Paribas, and HSBC have issued updated recommendations on Shree Cement, Larsen & Toubro (L&T), and Glenmark Pharma, emphasizing ...

Analysts recommend stocks such as HDFC Bank, Glenmark Pharmaceuticals, Tata Steel, and Samvardhana Motherson, expecting returns between 17%...

ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...

Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...

Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY...